Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

Next Previous
Trial Profile

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MOUNTAINEER

    • Most Recent Events

    • 02 Nov 2018 Planned End Date changed from 30 Jun 2021 to 30 Jun 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 15 May 2018 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top